

2015 (a)	First Quarter		Second Quarter		Third Quarter		Fourth Quarter		Total Year
	(b)		(c)		(d)		(e)
Net revenues	$	1,839	$	1,925	$	1,880	$	1,849	$	7,493
Gross profit	676		743		718		699		2,836

Income from continuing operations	70		129		354		200		753
Income from discontinued operations, net of taxes	—		—		—		—		—
Net income	70		129		354		200		753
Less: Net income attributable to noncontrolling interests	9		11		12		12		44
Net income attributable to Quest Diagnostics	$	61	$	118	$	342	$	188	$	709

Amounts attributable to Quest Diagnostics' stockholders:
Income from continuing operations	$	61	$	118	$	342	$	188	$	709
Income from discontinued operations, net of taxes	—		—		—		—		—
Net income	$	61	$	118	$	342	$	188	$	709

Earnings per share attributable to Quest Diagnostics' stockholders - basic:
Income from continuing operations	$	0.42	$	0.82	$	2.37	$	1.31	$	4.92
Income from discontinued operations	—		—		—		—		—
Net income	$	0.42	$	0.82	$	2.37	$	1.31	$	4.92

Earnings per share attributable to Quest Diagnostics' stockholders - diluted:
Income from continuing operations	$	0.42	$	0.81	$	2.35	$	1.29	$	4.87
Income from discontinued operations	—		—		—		—		—
Net income	$	0.42	$	0.81	$	2.35	$	1.29	$	4.87



2014 (a)	First Quarter		Second Quarter		Third Quarter		Fourth Quarter		Total Year
	(f)		(g)		(h)		(i)
Net revenues	$	1,746	$	1,902	$	1,904	$	1,883	$	7,435
Gross profit	645		728		726		699		2,798

Income from continuing operations	111		142		139		195		587
Income from discontinued operations, net of taxes	—		—		—		5		5
Net income	111		142		139		200		592
Less: Net income attributable to noncontrolling interests	7		9		10		10		36
Net income attributable to Quest Diagnostics	$	104	$	133	$	129	$	190	$	556

Amounts attributable to Quest Diagnostics' stockholders:
Income from continuing operations	$	104	$	133	$	129	$	185	$	551
Income from discontinued operations, net of taxes	—		—		—		5		5
Net income	$	104	$	133	$	129	$	190	$	556

Earnings per share attributable to Quest Diagnostics' stockholders - basic:
Income from continuing operations	$	0.72	$	0.92	$	0.89	$	1.27	$	3.80
Income from discontinued operations	—		—		—		0.03		0.03
Net income	$	0.72	$	0.92	$	0.89	$	1.30	$	3.83

Earnings per share attributable to Quest Diagnostics' stockholders - diluted:
Income from continuing operations	$	0.71	$	0.92	$	0.88	$	1.26	$	3.78
Income from discontinued operations	—		—		—		0.03		0.03
Net income	$	0.71	$	0.92	$	0.88	$	1.29	$	3.81

(a)

In April 2013, the Company completed the sale of HemoCue. During the third quarter of 2006, the Company completed its wind down of NID and classified the operations of NID as discontinued operations. Results of operations have been prepared to report the results of HemoCue and NID as discontinued operations for all periods presented (see Note 18). In July 2015, the Company contributed its clinical trials testing business to a newly formed global clinical trials central laboratory services joint venture, Q² Solutions. Subsequent to closing, the Company's ownership interest in the joint venture is being accounted for under the equity method of accounting.

(b)

Includes pre-tax charges of $31 million, primarily associated with workforce reductions and professional fees incurred in connection with further restructuring and integrating the Company ($20 million in cost of services and $11 million in selling, general and administrative expenses); pre-tax charges of $8 million in other operating expense (income), net, representing non-cash asset impairment charges associated with our Celera Products business; pre-tax charges in selling, general and administrative expenses of $2 million, principally representing costs incurred related to legal matters; and pre-tax charges of $79 million on retirement of debt associated with the March 2015 cash tender offer in other (expense) income, net (see Note 13).

(c)

Includes pre-tax charges of $23 million, primarily associated with workforce reductions and professional fees incurred in connection with further restructuring and integrating the Company ($11 million in cost of services and $12 million in selling, general and administrative expenses); a pre-tax gain included in other operating expense (income), net of $13 million associated with a decrease in the fair value of the contingent consideration accrual associated with our Summit Health acquisition (see Note 5 and Note 7); pre-tax charges in selling, general and administrative expenses of $5 million, principally representing costs incurred related to legal matters; pre-tax charges of $5 million in other operating expense (income), net, representing non-cash asset impairment charges; and pre-tax charges of $65 million on retirement of debt associated with the April 2015 redemption in other (expense) income, net (see Note 13).

(d)

Includes a pre-tax gain of $334 million associated with the contribution of the Company's clinical trials testing business to Q² Solutions (see Note 6); and pre-tax charges of $29 million, primarily associated with workforce reductions and professional fees incurred in connection with further restructuring and integrating the Company ($20 million in cost of services and $9 million in selling, general and administrative expenses).

(e)

Includes pre-tax charges of $22 million, primarily associated with workforce reductions and professional fees incurred in connection with further restructuring and integrating the Company ($12 million in cost of services and $10 million in selling, general and administrative expenses); pre-tax charges of $11 million in other operating expense (income), net, representing non-cash asset impairment charges associated with winding down a subsidiary; and pre-tax charges in selling, general and administrative expenses of $10 million, principally representing costs incurred related to legal matters. Income from continuing operations includes a deferred income tax benefit of $58 million associated with winding down a subsidiary.

(f)

Includes pre-tax charges of $24 million, primarily associated with workforce reductions and professional fees incurred in connection with further restructuring and integrating the Company ($12 million in cost of services and $12 million in selling, general and administrative expenses); and pre-tax charges in selling, general and administrative expenses of $4 million, principally representing costs incurred related to legal matters.

(g)

Includes pre-tax charges of $27 million, primarily associated with workforce reductions and professional fees incurred in connection with further restructuring and integrating the Company ($11 million in cost of services and $16 million in selling, general and administrative expenses); and pre-tax charges in selling, general and administrative expenses of $7 million, principally representing costs incurred related to legal matters.

(h)

Includes pre-tax charges of $40 million, primarily associated with workforce reductions and professional fees incurred in connection with further restructuring and integrating the Company ($14 million in cost of services, $25 million in selling, general and administrative expenses and $1 million in other operating expense (income), net); and pre-tax charges in selling, general and administrative expenses of $8 million, principally representing costs incurred related to legal matters.

(i)

Includes pre-tax charges of $30 million, primarily associated with workforce reductions and professional fees incurred in connection with further restructuring and integrating the Company ($13 million in cost of services, $16 million in selling, general and administrative expenses and $1 million in other operating expense (income), net); pre-tax charges in selling, general and administrative expenses of $5 million, principally representing costs incurred related to legal matters; and a pre-tax gain included in other operating expense (income), net of $9 million associated with a decrease in the fair value of the contingent consideration accrual associated with the Summit Health acquisition (see Note 5 and Note 7). Income from continuing operations includes a discrete benefit of $44 million associated with the favorable resolution of certain tax contingencies.